Uromigos-ASCO GU

The UromigosThe Uromigos | March 7, 2023
Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium.
Listen Now
The UromigosThe Uromigos | February 27, 2023
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
The UromigosThe Uromigos | February 21, 2023
Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos.
The UromigosThe Uromigos | February 21, 2023
Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx.
The UromigosThe Uromigos | February 21, 2023
Christian Kollmannsberger, MD, FRCPC, discusses his presentation on utilizing miR371 as a biomarker for germ cell tumors.
The UromigosThe Uromigos | February 18, 2023
Neeraj Agarwal, MD, FASCO, describes positive data from the TALAPRO-2 study on talazoparib and enzalutamide for mCRPC.
The UromigosThe Uromigos | February 18, 2023
Michael Morris, MD discusses PARP inhibition for castration-resistant prostate cancer and the differing opinions on its use.
The UromigosThe Uromigos | February 18, 2023
Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the IMvigor130 study.
The UromigosThe Uromigos | February 18, 2023
Andrea Necchi, MD describes the results of the phase 2 KEYNOTE-057 study at the 2023 ASCO GU Cancers Symposium.
The UromigosThe Uromigos | February 19, 2022
Axel Bex, MD, PhD, from the Netherlands Cancer Institute, Amsterdam, described results of the NeoAvAx trial as ...
The UromigosThe Uromigos | February 19, 2022
Dr. Fred Saad describes the results of the PROpel Phase III trial.
The UromigosThe Uromigos | February 18, 2022
Dr. Jonathan Rosenberg describes the results of this positive randomized phase 2 trial.
The UromigosThe Uromigos | February 18, 2022
Dr Petros Grivas describes the results of this phase 2 trial.
The UromigosThe Uromigos | February 17, 2022
Kim Chi, MD, describes the results of the MAGNITUDE trial,
The UromigosThe Uromigos | February 17, 2022
Results from the ARASENS trial appear to have confirmed triple therapy as the new standard of care for mHSPC.
The UromigosThe Uromigos | February 10, 2022
Pete Nelson, MD, describes mechanism of action and current clinical application in prostate cancer.
Advertisement
Advertisement